NCCN task force report: molecular markers in leukemias and lymphomas.

摘要: The introduction of targeted therapies has revolutionized treatment and improved outcomes in patients with leukemias lymphomas. However, many experience relapse caused by the persistence residual malignant cells. Cytogenetic molecular techniques are increasingly being used to assess quantify minimal disease (MRD). emergence advanced technologies led discovery multiple novel markers that can be detect MRD predict outcome Gene expression signatures clinical non-Hodgkin's lymphoma have been identified. In chronic myelogenous leukemia, monitoring become more important assessing response detecting resistance therapy. acute leukemias, several new shown potential prognostication treatment. lymphomas, microRNAs identified may useful diagnostics prognostication. To address these issues, National Comprehensive Cancer Network (NCCN) organized a task force consisting panel experts leukemia discuss recent advances field MRD.